Meropenem is a powerful antibiotic given intravenously to treat serious bacterial infections, including complicated abdominal infections, skin infections, and bacterial meningitis. It belongs to the carbapenem class, often considered a last line of defense when other antibiotics fail or when infections involve resistant bacteria.
How Meropenem Works
Bacteria survive by constantly building and reinforcing their cell walls. Meropenem stops this process by permanently binding to the enzymes bacteria use to cross-link the building blocks of their cell walls. Without intact walls, bacterial cells weaken and die. This mechanism is shared across the broader family of beta-lactam antibiotics (which includes penicillins), but carbapenems like meropenem are uniquely resistant to the defensive enzymes many bacteria produce to break down other antibiotics. That stability against bacterial defenses is what makes meropenem effective where narrower antibiotics often aren’t.
Infections Meropenem Treats
Meropenem is FDA-approved for three primary types of infection in adults:
- Complicated intra-abdominal infections: infections that spread beyond a single organ in the abdomen, such as a ruptured appendix leading to peritonitis or an abdominal abscess.
- Complicated skin and skin structure infections: deep or spreading skin infections that haven’t responded to first-line treatments, including those caused by Pseudomonas aeruginosa, a notoriously hard-to-treat bacterium.
- Bacterial meningitis: specifically in children 3 months and older, where it’s approved to treat meningitis caused by Haemophilus influenzae, Neisseria meningitidis, and certain strains of Streptococcus pneumoniae.
In practice, doctors also use meropenem off-label for a wider range of severe infections, including hospital-acquired pneumonia, bloodstream infections (sepsis), and urinary tract infections caused by multidrug-resistant organisms. The Infectious Diseases Society of America recommends meropenem as part of combination therapy for healthcare-associated meningitis and ventriculitis in adults as well.
What It Covers: Bacterial Spectrum
One of the reasons meropenem is so widely relied upon in hospitals is its exceptionally broad spectrum. It’s active against gram-positive bacteria (like Staphylococcus aureus and penicillin-resistant pneumococci), gram-negative bacteria (like E. coli, Pseudomonas aeruginosa, and Burkholderia cepacia), and anaerobes (bacteria that thrive without oxygen, such as Bacteroides fragilis and Clostridium perfringens). Comparative studies show meropenem is often more potent than imipenem, a related carbapenem, particularly against gram-negative organisms including Pseudomonas.
This broad coverage makes meropenem a go-to choice when the specific bacterium causing an infection hasn’t been identified yet, or when cultures reveal a resistant organism that shrugs off other antibiotics.
How It’s Given
Meropenem is administered only through an IV, either in a hospital or sometimes through a home infusion service. Each dose is typically infused over 15 to 30 minutes, though higher doses can sometimes be pushed more quickly over 3 to 5 minutes. The standard schedule is every 8 hours, meaning three doses per day.
For skin infections, the typical adult dose is 500 mg per infusion. For abdominal infections and skin infections involving Pseudomonas, the dose increases to 1 gram. In pediatric meningitis, dosing is weight-based at 40 mg per kilogram every 8 hours, capped at 2 grams per dose for children over 50 kg. Treatment courses vary by infection but commonly last 5 to 14 days.
Meningitis and the Blood-Brain Barrier
Treating meningitis requires an antibiotic that can cross from the bloodstream into the cerebrospinal fluid surrounding the brain and spinal cord. Meropenem does cross this barrier, but its penetration is low, averaging around 6%, and varies widely from patient to patient (with an 84% coefficient of variation in studies). This means that reaching effective drug levels in the cerebrospinal fluid can be unpredictable, and higher doses are often needed. Despite this limitation, meropenem remains one of the preferred options for bacterial meningitis because many alternative antibiotics penetrate even less reliably or lack coverage against the relevant organisms.
Common Side Effects
The most frequently reported side effects, occurring in 2% or more of patients, include headache, nausea, diarrhea, constipation, vomiting, anemia, and rash. These are generally manageable and often resolve once treatment ends.
Seizures are a concern with carbapenem antibiotics broadly, but meropenem carries a relatively low risk. In clinical trials involving nearly 3,000 adults treated for non-brain infections, the seizure rate was 0.7%. In meningitis studies, seizure rates during meropenem therapy were comparable to those seen with other standard antibiotics like ceftriaxone. This lower seizure risk compared to some older carbapenems is one reason meropenem became the preferred carbapenem for many clinicians.
Important Drug Interaction With Seizure Medication
If you or a family member takes valproic acid (a common seizure and mood-stabilizing medication), this interaction is critical to know about. Meropenem, and all carbapenems, can slash valproic acid blood levels by 60 to 100% within roughly two days. This drop is so large and so fast that simply monitoring levels or adjusting the valproic acid dose won’t compensate. The UK’s Medicines and Healthcare products Regulatory Agency explicitly recommends against using the two together because the interaction can lead to breakthrough seizures. If meropenem is necessary, an alternative seizure medication is typically used for the duration of treatment.
Who Should Not Receive Meropenem
People with a known allergy to meropenem or other carbapenems should not receive it. There is some cross-reactivity with penicillin allergies, so your medical team will evaluate your allergy history carefully. Safety data in children younger than 3 months is not established, and there is no pediatric data for patients with kidney impairment. Adults with reduced kidney function typically need dose adjustments because meropenem is cleared through the kidneys, and impaired clearance can lead to the drug accumulating to higher-than-intended levels.
Why Meropenem Is Reserved for Serious Infections
Despite its effectiveness, meropenem is not a first-choice antibiotic for routine infections. Overuse of carbapenems accelerates the development of carbapenem-resistant bacteria, which are among the most dangerous drug-resistant organisms worldwide. Hospitals typically restrict meropenem to situations where narrower antibiotics have failed, where cultures confirm a resistant pathogen, or where the infection is severe enough that broad coverage is needed immediately while awaiting test results. This stewardship approach helps preserve meropenem’s effectiveness for the patients who need it most.